Stay updated on MBG453 Combo with Azacitidine & Venetoclax Clinical Trial
Sign up to get notified when there's something new on the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page.

Latest updates to the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page
- Check4 days agoChange DetectedThe history page adds a new entry 'Revision: v3.3.3' and removes the footer items 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision from v3.2.0 to v3.3.2 is reflected on the page; no study data or page content is affected.SummaryDifference0.1%

- Check40 days agoChange DetectedNovartis decided to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following negative results from two other trials. The history also removes a government-funding notice and records that the study was terminated due to negative results across the program.SummaryDifference0.8%

- Check54 days agoChange DetectedThe new screenshot shows a refreshed layout of the Record History page with the same study information and version list as the old screenshot, indicating no substantive edits to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page now adds a complete study protocol/results framework and status metadata, significantly expanding core content; nothing was removed.SummaryDifference3%

- Check76 days agoChange DetectedUpgrade notice issued: new funding/status notice and v3.2.0 release replaces v3.1.0; page now publicly states current version and operating status details.SummaryDifference9%

Stay in the know with updates to MBG453 Combo with Azacitidine & Venetoclax Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MBG453 Combo with Azacitidine & Venetoclax Clinical Trial page.